| abstract |
NTNR alpha , NTNR alpha extracellular domain (ECD), NTNR alpha variants, chimeric NTNR alpha (e.g., NTNR alpha immunoadhesin), and antibodies which bind thereto (including agonist and neutralizing antibodies) are disclosed. Various uses for these molecules are described, including methods to modulate cell activity and survival by response to NTNR alpha -ligands, for example NTN, by providing NTNR alpha to the cell. |